Stay updated on the latest breakthroughs in biotechnology. From advancements in gene editing technologies like CRISPR to developments in cell and gene therapies, explore how biotech is driving medical innovation and transforming patient care.
Quick Summary Deal Value: AbbVie acquires Aliada Therapeutics for $1.4 billion. Strategic Focus: Expands AbbVie’s central nervous system (CNS) and oncology capabilities. Therapeutic Goals: Strengthening
Quick Summary Contract Value: $1.24 billion—the largest single contract for Samsung Biologics to date. Client: An Asia-based pharmaceutical company. Production Location: Songdo, South Korea, at
Quick Summary Investment Amount: Agomab Therapeutics raised $89 million in Series D financing. Key Backers: Led by new investors Sanofi and Invus, with participation from
Merck & Co. has acquired Modifi Biosciences, a precision oncology biotech, in a deal that includes a $30 million upfront payment and potential milestones totaling
Novartis’ €2.7 Billion Investment in MorphoSys Hits Setback as Safety Signal Delays Key Drug Filing Novartis’ recent acquisition of MorphoSys aimed to bring promising therapies
Resolution Therapeutics has secured $85 million in new funding to continue developing its macrophage-based therapies for liver diseases. The company is leveraging the natural regenerative
In an exciting new development, Booster Therapeutics has entered the biotech space with a $15 million seed funding round. The company, which officially launched on
Cambridge-based biotech company Shift Bioscience has raised $16 million in seed funding to drive forward its cellular reprogramming research aimed at combating age-related diseases. The
The healthcare landscape is evolving rapidly, driven by groundbreaking advancements in biotechnology, medical technology, and pharmaceuticals. As investors and industry observers look ahead to 2025,
Biotechnology is advancing rapidly, driving innovation across healthcare, agriculture, food, and manufacturing. At the forefront of these advancements are gene editing technologies like CRISPR/Cas9, which
